Plant Name: Valeriana jatamansi
Taxonomic Information:
Plant ID: NPO29016
Plant Latin Name: Valeriana jatamansi
Taxonomy Genus: Valeriana
Taxonomy Family: Caprifoliaceae
Plant External Links:
NCBI TaxonomyDB:
59170
Plant-of-the-World-Online:
60458931-2
Used in Medicines:
Country/Region:
IndiaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Ayurveda; SiddhaGeographical Distribution:
India; Nepal; China; Vietnam; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR1B; HTR1D; HTR2A; HTR2C; HTR6; | |
| TSHR; | |
| MPO; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
| Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 4.763E-13 | 2.593E-09 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 4.763E-13 | 2.593E-09 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 1.193E-11 | 3.711E-08 | HTR1B, HTR1D, HTR2A, HTR2C |
| BP | GO:0023052; signaling | GO:0007268; chemical synaptic transmission | 1.807E-07 | 2.918E-04 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 2.412E-07 | 2.918E-04 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 2.412E-07 | 2.918E-04 | HTR2A, HTR2C |
| BP | Unclassified; | GO:0042310; vasoconstriction | 3.625E-07 | 4.155E-04 | HTR1B, HTR1D, HTR2A |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 2.410E-06 | 2.099E-03 | HTR2A, HTR2C |
| BP | GO:0007610; behavior | GO:0050795; regulation of behavior | 4.095E-06 | 3.302E-03 | HTR1B, HTR1D, HTR2A |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 2.423E-05 | 1.426E-02 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6, TSHR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.297E-05 | 1.709E-02 | CYP1A2, CYP2A6, MPO |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.240E-09 | 1.743E-08 | HTR6, HTR1D, HTR1B, HTR2C, HTR2A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.341E-09 | 1.743E-08 | HTR6, HTR1D, HTR1B, HTR2C, HTR2A, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.906E-06 | 1.461E-05 | HTR6, HTR1D, HTR1B, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 8.213E-05 | 4.271E-04 | HTR6, HTR2C, HTR2A |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.602E-04 | 1.886E-03 | CYP2A6, CYP1A2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 5.185E-04 | 1.886E-03 | CYP2A6, CYP1A2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.802E-04 | 1.886E-03 | CYP2A6, CYP1A2 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04742 | Taste transduction | 7.493E-04 | 1.948E-03 | HTR1D, HTR1B |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.042E-03 | 2.259E-03 | HTR2C, HTR2A |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 8.418E-04 | 1.990E-03 | HTR2C, HTR2A |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.315E-04 | 1.948E-03 | CYP2A6, CYP1A2 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.248E-06 | 1.461E-05 | CYP2A6, CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; HTR1B; HTR1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2A; HTR2C; HTR6; HTR1B; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; HTR2C; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR6; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR2C; HTR1B; HTR1D; |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR2A; |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HTR1D; |
| NA: NA | Addiction | NA | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | HTR1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2A; HTR2C; HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; HTR1B; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2A; HTR1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR2C; HTR1B; HTR1D; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; HTR6; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; HTR6; |
| NA: NA | Primary insomnia | NA | HTR2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR6; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR2C; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
